Reduction in IL-6 levels translated into decreased tumour activity, indicating the central role of the IL-6/Janus kinase 2 (JAK2)/STAT3 pathway in the mechanism of action of BBR [28]. The gene discussed is JAK2; the disease is neoplasm.